{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:42:02Z","timestamp":1789274522805,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jcyt.2025.08.002","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T02:22:28Z","timestamp":1755742948000},"page":"1396-1407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and qualification of a sensitive method for residual feeder cell detection in NK cell therapy products"],"prefix":"10.1016","volume":"27","author":[{"given":"Elizabeth","family":"Castro-Rivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0311-1585","authenticated-orcid":false,"given":"Alexandra","family":"Aquino-Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9425-6829","authenticated-orcid":false,"given":"Myraida","family":"Toledo-Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Avil\u00e9s-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Ayala-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2399-5715","authenticated-orcid":false,"given":"Eliezer","family":"Romeu-Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8820-8846","authenticated-orcid":false,"given":"Ivone","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.08.002_bib0001","doi-asserted-by":"crossref","first-page":"1192907","DOI":"10.3389\/fimmu.2023.1192907","article-title":"Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond","volume":"14","author":"Shin","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jcyt.2025.08.002_bib0002","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.08.002_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1202950","article-title":"Beyond alphabeta T cells: NK, iNKT, and gammadeltaT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML","volume":"14","author":"Kent","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jcyt.2025.08.002_bib0004","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.immuni.2018.05.010","article-title":"Innate Lymphoid Cell Development: a T Cell Perspective","volume":"48","author":"Cherrier","year":"2018","journal-title":"Immunity"},{"issue":"21","key":"10.1016\/j.jcyt.2025.08.002_bib0005","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jcyt.2025.08.002_bib0006","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nri3044","article-title":"NK cell development, homeostasis and function: parallels with CD8(+) T cells","volume":"11","author":"Sun","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.jcyt.2025.08.002_bib0007","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"8000","key":"10.1016\/j.jcyt.2025.08.002_bib0008","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jcyt.2025.08.002_bib0009","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jcyt.2025.08.002_bib0010","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jcyt.2025.08.002_bib0011","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","article-title":"Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy","volume":"43","author":"Ma","year":"2022","journal-title":"Trends Immunol"},{"issue":"4","key":"10.1016\/j.jcyt.2025.08.002_bib0012","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41423-021-00808-3","article-title":"Advances in NK cell production","volume":"19","author":"Fang","year":"2022","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"10.1016\/j.jcyt.2025.08.002_bib0013","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1182\/blood-2007-09-110312","article-title":"Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components","volume":"111","author":"Alici","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jcyt.2025.08.002_bib0014","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.186890","article-title":"Interim report on engineered NK cell trial in lung cancer refractory to immune checkpoint inhibitors","volume":"10","author":"Villalona-Calero","year":"2025","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.jcyt.2025.08.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.jcyt.2025.08.002_bib0016","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-08-3712","article-title":"Expansion of highly cytotoxic human natural killer cells for cancer cell therapy","volume":"69","author":"Fujisaki","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2025.08.002_bib0017","series-title":"Validation of analytical procedures\u201d Q2(R2)","year":"2023"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2025.08.002_bib0018","first-page":"S49","article-title":"Limit of blank, limit of detection and limit of quantitation","volume":"29 Suppl 1","author":"Armbruster","year":"2008","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.jcyt.2025.08.002_bib0019","unstructured":"Title 21 part 610\u2014general biological products standards. [Online]. Available: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-F\/part-610"},{"key":"10.1016\/j.jcyt.2025.08.002_bib0020","unstructured":"(2024). Considerations for the Use of Human- and Animal-Derived Materials in the Manufacture of Cellular and Gene Therapy and Tissue-Engineered Medical Products."},{"key":"10.1016\/j.jcyt.2025.08.002_bib0021","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.omtm.2023.05.007","article-title":"Development and validation of a model gene therapy biodistribution assay for AVGN7 using digital droplet polymerase chain reaction","volume":"29","author":"Rodgers","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"10.1016\/j.jcyt.2025.08.002_bib0022","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-2836(05)80360-2","article-title":"Basic local alignment search tool","volume":"215","author":"Altschul","year":"1990","journal-title":"J Mol Biol"},{"issue":"1","key":"10.1016\/j.jcyt.2025.08.002_bib0023","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1038\/s41598-017-02217-x","article-title":"Droplet Digital PCR versus qPCR for gene expression analysis with low abundant targets: from variable nonsense to publication quality data","volume":"7","author":"Taylor","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jcyt.2025.08.002_bib0024","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1038\/s41598-018-21882-0","article-title":"Normalization of cell associated antiretroviral drug concentrations with a novel RPP30 droplet digital PCR assay","volume":"8","author":"Dyavar","year":"2018","journal-title":"Sci Rep"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925008096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925008096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:10:26Z","timestamp":1772889026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925008096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1465324925008096"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.08.002","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and qualification of a sensitive method for residual feeder cell detection in NK cell therapy products","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}